Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Molecular patterns of response and treatment failure after frontline ventoclax combinations in older patients with AML

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of durable remission, response followed by relapse (adaptive resistance), or refractory disease (primary resistance). High response rates and durable remissions were typically associated with NPM1 or IDH2 mutations, with prolonged molecular remissions prevalent for NPM1 mutations. Primary and adaptive resistance to venetoclax-based combinations was most commonly characterized by ac- quisition or enrichment of clones activating signaling pathways such as FLT3 or RAS or biallelically perturbing TP53. Single-cell studies highlighted the polyclonal nature of intratumoral resistance mechanisms in some cases. Among cases that were primary re- fractory, we identified heterogeneous and sometimes divergent interval changes in leu- kemic clones within a single cycle of therapy, highlighting the dynamic and rapid occurrence of therapeutic selection in AML. In functional studies, FLT3 internal tandem duplication gain or TP53 loss conferred cross-resistance to both venetoclax and cytotoxic-based therapies.

Collectively, we highlight molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies. (Blood. 2020;135(11):791-803)


DOWNLOAD
publication
Identification and genetic analysis of cancer cells with PCR-activated cell sorting
Department of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California, San Francisco; Mission Bio, Inc., San Francisco, CA
Eastburn, D., et al., Nucleic Acids Research (2014)
publication
Microfluidic droplet enrichment for targeted sequencing
Department of Bioengineering and Therapeutic Sciences, California Institute for Quantitative Biosciences, University of California, San Francisco; Mission Bio, Inc., San Francisco, CA
Eastburn, D. et. al., Nucleic Acids Research (2015)
publication
RNA-Seq following PCR-based sorting reveals rare cell transcriptional signatures
Mission Bio, Inc. South San Francisco, CA, USA
Pellegrino, M., et. al., BMC Genomics (2016)
publication
Differential roles for Lgr5 and Lgr6 in epidermal stem cell lineage selection and squamous tumour development
Helen Diller Family Comprehensive Cancer Center University of California, San Francisco; Genome Institute of Singapore, Singapore
Huang, P., et. al., Nature Genetics (2017)
REQUEST QUOTE